From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts
 | Early-irAEs (patients-%) | Late-irAEs (patients-%) | P value |
---|---|---|---|
Any grade irAEs | 175 | 110 | Â |
Single-site irAEs | 112 (64.0) | 93 (84.5) | 0.1339 |
Multiple-site irAEs | 63 (36.0) | 17 (15.4) | 0.0040 |
Management | |||
 No intervention (only supportive) | 87 (49.7) | 55 (50.0) | 0.9783 |
 Corticosteroids without discontinuation | 69 (39.4) | 38 (34.5) | 0.5754 |
 Corticosteroids with temporary discontinuation | 19 (10.9) | 6 (5.5) | 0.1488 |
 Corticosteroids with permanent discontinuation | – | 11 (10) | 0.0001 |